Use of sonodynamic therapy for the treatment of medication-related osteonecrosis of the jaw

Effects of Sonodynamic Therapy (SDT) in Patients with Medication-Related Osteonecrosis: A preliminary study. - SDT Sonodynamic Therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-7y2ck4f

Enrollment

Registered

2026-04-13

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteonecrosis

Interventions

This is an interventional clinical study, non-randomized, single-arm, open-label, involving a total of 6 participants, all allocated to a single experimental group, with no control group. No randomiza

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients aged 18 years or older; diagnosis of medication-related osteonecrosis of the jaw (mronj) according to ruggiero criteria; history of exposure to bone-modifying agents; presence of exposed necrotic bone; ability to understand and comply with the treatment protocol

Exclusion criteria

Exclusion criteria: history of head and neck radiotherapy; presence of active malignant disease in the oral cavity; inability to perform oral hygiene; known allergy to methylene blue

Design outcomes

Primary

Measure	Time frame
To evaluate clinical improvement of medication-related osteonecrosis of the jaw; verified using the Ruggiero staging classification; reduction in clinical stage, absence of bone exposure or presence of intact mucosa was observed during follow-up	—

Secondary

Measure	Time frame
to evaluate pain reduction; verified using the visual analog scale; a decrease in reported numerical values was observed during follow-up;to evaluate reduction of clinical signs of infection; verified through clinical examination; a decrease in erythema, edema and purulent discharge was observed during follow-up;to evaluate sequestra formation and elimination; verified through clinical and radiographic examination; presence, reduction or elimination of bone fragments was observed during follow-up;to evaluate tissue repair of the affected area; verified through clinical examination; mucosal coverage of previously exposed bone and signs of healing were observed during follow-up	—

Measure

Time frame

to evaluate pain reduction; verified using the visual analog scale; a decrease in reported numerical values was observed during follow-up;to evaluate reduction of clinical signs of infection; verified through clinical examination; a decrease in erythema, edema and purulent discharge was observed during follow-up;to evaluate sequestra formation and elimination; verified through clinical and radiographic examination; presence, reduction or elimination of bone fragments was observed during follow-up;to evaluate tissue repair of the affected area; verified through clinical examination; mucosal coverage of previously exposed bone and signs of healing were observed during follow-up

—

Countries

Contacts

Public ContactVictor Montalli

Faculdade São Leopoldo Mandic

victormontalli@gmail.com+5519983511200

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: May 1, 2026